rs147804855
Variant summary
Our verdict is Uncertain significance. The variant received 1 ACMG points: 2P and 1B. BP4PM2_SupportingPS3_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_001482.3:c.314C>T variant in GATM is a missense variant that is predicted to result in the substitution of proline by leucine and amino acid position 105 (p.Pro105Leu). To our knowledge, this variant has not been reported in an individual with AGAT deficiency in the published literature. It is absent in gnomAD v4.1.0. (PM2_Supporting). When overexpressed in HeLa cells, the variant resulted in 0.6% wild-type activity (PMID:27233232; ClinVar Variation ID: 225913 - see Germline Functional Evidence section) which is below the threshold of the CCDS VCEP of <15% wild-type activity, indicating the the variant may impact the function of the protein (PS3_Supporting). The computational predictor REVEL gives a score of 0.066 which is below the threshold of 0.29, evidence that does not predict a damaging effect on AGAT function (BP4). There is a ClinVar entry for this variant (Variation ID: 225913). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for AGAT deficiency. GATM-specific ACMG/AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 2.0.0): PS3_Supporting, PM2_Supporting, BP4.(Classification approved by the ClinGen CCDS VCEP on April 11, 2025). LINK:https://erepo.genome.network/evrepo/ui/classification/CA270169359/MONDO:0012996/025
Frequency
Consequence
NM_001482.3 missense
Scores
Clinical Significance
Conservation
Publications
- AGAT deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Ambry Genetics, G2P
- Fanconi renotubular syndrome 1Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- primary Fanconi syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 1 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GATM | NM_001482.3 | c.314C>T | p.Pro105Leu | missense_variant | Exon 3 of 9 | ENST00000396659.8 | NP_001473.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Arginine:glycine amidinotransferase deficiency Uncertain:1
The NM_001482.3:c.314C>T variant in GATM is a missense variant that is predicted to result in the substitution of proline by leucine and amino acid position 105 (p.Pro105Leu). To our knowledge, this variant has not been reported in an individual with AGAT deficiency in the published literature. It is absent in gnomAD v4.1.0. (PM2_Supporting). When overexpressed in HeLa cells, the variant resulted in 0.6% wild-type activity (PMID: 27233232; ClinVar Variation ID: 225913 - see Germline Functional Evidence section) which is below the threshold of the CCDS VCEP of <15% wild-type activity, indicating the the variant may impact the function of the protein (PS3_Supporting). The computational predictor REVEL gives a score of 0.066 which is below the threshold of 0.29, evidence that does not predict a damaging effect on AGAT function (BP4). There is a ClinVar entry for this variant (Variation ID: 225913). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for AGAT deficiency. GATM-specific ACMG/AMP criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 2.0.0): PS3_Supporting, PM2_Supporting, BP4. (Classification approved by the ClinGen CCDS VCEP on April 11, 2025). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at